Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Medical Oncology
•
NCI-CCC Tumor Board Question
•
Moffitt Cancer Center
•
HR+
•
NCI-CCC Breast Tumor Board Question
•
Breast Cancer, Non-metastatic
How do you council patients diagnosed with hormone receptor-positive breast cancer currently or interested in taking exogenous hormones (e.g. testosterone) for gender-affirming treatment?
Related Questions
What estimated absolute benefit level of adjuvant chemotherapy for HR-pos HER2-negative breast cancer is worth recommending chemotherapy to patients?
In which scenarios do you stage breast cancer using CT and nuclear bone scans versus PET-CT?
Are there any scenarios you would use CDK 4/6i to treat HR-positive HER2-positive breast cancer in combination with anti-HER2 agents?
In which scenarios do you use vaginal estrogen in patients with history of HR positive breast cancer?
Do you consider post-NAC isolated tumor cells in LNs to be residual disease in TNBC to justify capecitabine?
How do you approach ovarian function suppression in premenopausal women with HR+/HER2-, node negative breast cancer and intermediate OncoType dx scores (11-25) who received chemotherapy?
What adjuvant systemic therapy would you give a patient with pN2 nodal relapse of ER+/HER2- breast cancer now s/p ALND, after initial mastectomy, adjuvant TC, and 5 years of endocrine therapy?
In which situations are you comfortable with alternative dosing of ovarian suppression (e.g Lupron q3m) for premenopausal patients during adjuvant breast cancer treatment?
How would you approach adjuvant therapy for large (≥4 cm), node negative, HR+, HER2- breast cancer in an elderly woman with comorbidities including neuropathy?
Does the degree of hormone receptor positivity influence your decision to perform Oncotype testing?
